perpetuity. It is made available under a CC-BY 4.0 International license .

The mediating role of mammographic density in the protective effect of 1 early-life adiposity on breast cancer risk: a multivariable Mendelian 2 randomization study 3

4

5

Marina Vabistsevits^{1, 2*}, George Davey Smith^{1, 2}, Tom G. Richardson^{1, 2}, Rebecca C. Richmond^{1, 2}, Weiva Sieh^{3,4}, Joseph H. Rothstein^{3,4}, Laurel A. Habel⁵, Stacey E. Alexeeff⁵, Bethan Lloyd-Lewis⁶ 6 & Eleanor Sanderson^{1, 2} 7 8 1 - University of Bristol, MRC Integrative Epidemiology Unit, Bristol, United Kingdom, 9 2 - University of Bristol, Population Health Sciences, Bristol, United Kingdom, 10 3 - Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic 11 Sciences, Department of Population Health Science and Policy, New York, NY, United 12 States. 13 4 - University of Texas MD Anderson Cancer Center, Department of Epidemiology, Houston,

- 14 TX, United States,
- 5 Kaiser Permanente Northern California, Division of Research, Oakland, CA, United 15 16 States.
- 17 6 - University of Bristol, School of Cellular and Molecular Medicine, Bristol, United Kingdom
- 18

19 * Corresponding author: Marina Vabistsevits, MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol 20 Medical School, University of Bristol, UK. E-mail: marina.vabistsevits@bristol.ac.uk

21

Abstract 22

23

24 Observational studies suggest that mammographic density (MD) may have a role in the unexplained 25 protective effect of childhood adiposity on breast cancer risk. Here, we investigated a complex and 26 interlinked relationship between puberty onset, adiposity, MD, and their effects on breast cancer using 27 Mendelian randomization (MR).

28

29 We estimated the effects of childhood and adulthood adiposity, and age at menarche on MD 30 phenotypes (dense area (DA), non-dense area (NDA), percent density (PD)) using MR and 31 multivariable MR (MVMR), allowing us to disentangle their total and direct effects. Next, we examined 32 the effect of MD on breast cancer risk, including risk of molecular subtypes, and accounting for genetic 33 pleiotropy. Finally, we used MVMR to evaluate whether the protective effect of childhood adiposity on 34 breast cancer was mediated by MD.

35

36 Childhood adiposity had a strong inverse effect on mammographic DA, while adulthood adiposity 37 increased NDA. Later menarche had an effect of increasing DA and PD, but when accounting for 38 childhood adiposity, this effect attenuated to the null. DA and PD had a risk-increasing effect on breast 39 cancer across all subtypes. The MD single-nucleotide polymorphism (SNP) estimates were extremely 40 heterogeneous, and examination of the SNPs suggested different mechanisms may be linking MD 41 and breast cancer. Finally, MR mediation analysis estimated that 56% (95% CIs [32% - 79%]) of the 42 childhood adiposity effect on breast cancer risk was mediated via DA.

43

44 In this work, we sought to disentangle the relationship between factors affecting MD and breast cancer. 45 We showed that higher childhood adiposity decreases mammographic DA, which subsequently leads 46 to reduced breast cancer risk. Understanding this mechanism is of great importance for identifying 47 potential targets of intervention, since advocating weight gain in childhood would not be

48 recommon bear and the second sec

perpetuity. It is made available under a CC-BY 4.0 International license .

49 Introduction

50

51 Breast cancer is the most common cancer in women worldwide [1]. Incidence rates continue to rise 52 globally [2], and thus there is an urgent need to identify new and modifiable breast cancer risk factors. 53 It is also critical to investigate the links between protective traits and breast cancer as those may reveal 54 new mechanisms for targeted intervention. Observational and Mendelian randomization (MR) studies 55 have shown that adiposity in childhood may reduce the risk of breast cancer in later life [3]-[7], and 56 that this effect is direct and independent of adult body size. MR is an approach to causal inference 57 that uses genetic variants as instrumental variables (IVs) to infer whether a modifiable health exposure 58 influences a disease outcome [8] [9]. In previous work [10], we used an MR framework to investigate 59 the biological mechanism underlying the protective effect of childhood adiposity by reviewing several 60 potential mediators, including hormonal, reproductive, and glycaemic traits. However, none of the 61 investigated mediators sufficiently explained the protective effect of childhood adiposity on breast 62 cancer risk. A mediator that has not yet been thoroughly investigated is mammographic density (MD), 63 an established risk factor for breast cancer [11], [12].

64

65 MD refers to the radiological appearance of fibroglandular vs adipose tissue in the breast and is 66 frequently quantified in three phenotypes: dense area (fibroglandular tissue, DA), non-dense area 67 (adipose tissue, NDA) and percent density (dense area as a proportion of total breast size, PD). DA 68 and PD are associated with an increased risk of breast cancer, whereas NDA is independently 69 associated with a decreased risk [13]. A high DA and PD elevate breast cancer risk as tumours are 70 more likely to arise in fibrous tissue, as well as being more difficult to detect in dense areas on a 71 mammography exam [14]. MD is highly heritable [15] and the risk of developing cancer is 4-6 fold 72 higher in women with extremely dense vs fatty breasts [14], but MD appears to be similarly associated 73 with all breast cancer molecular subtypes [16], [17]. Although the association between MD and breast 74 cancer is well-established, the molecular and cellular events that lead to the development of MD and 75 why it is associated with increased cancer risk are not well understood [18]. 76

77 Growing evidence points to associations between childhood adiposity, puberty onset, and adult 78 mammographic density (reviewed in [18]). Puberty is a critical time for breast development, during 79 which the breast epithelial and stromal compartments undergo extensive growth and tissue 80 remodelling [19]. Later age at menarche has been shown to positively associate with higher MD [20], 81 [21], despite being associated with a decreased risk of breast cancer [22] [23]. Adiposity at different 82 developmental stages also affects MD, as increased body size in adolescence is associated with a 83 higher abundance of adipose non-dense tissue and lower dense area and percent density in adulthood 84 [18], [20], [24], [25]. Childhood adiposity also has a well-established effect of decreasing age at 85 menarche [26], which in turn leads to higher adult adiposity [27]. Taken together, these traits appear 86 to have a complex and interlinked relationship that impacts breast development and growth, and 87 ultimately breast cancer risk. Several recent observational studies have suggested that childhood 88 adiposity may confer long-term protection against breast cancer via its effect on mammographic breast 89 density [28]–[31]. The effect of MD on breast cancer has also been analysed using different MR 90 methods [10], [32], [33]. While the overall picture reported from these studies supported 91 observationally known associations, there were some differences depending on the MR method 92 employed suggesting sensitivity to the underlying assumptions.

93

Here, we explore the mediating role of mammographic density in the protective effect of high childhood
adiposity on breast cancer risk, using data from genome-wide association study (GWAS) studies of
childhood body size, adult body size, age at menarche, mammographic density, and breast cancer
within a Mendelian randomization framework.

- 98
- 99 100
- 100
- 101
- 102
- 103
- 104
- 105

perpetuity. It is made available under a CC-BY 4.0 International license .

106 Results

107

108 Study overview

109

110 In this study, we aimed to investigate the mediating role of mammographic density in the protective 111 effect of childhood adiposity on breast cancer risk. Figure 1 presents a flow diagram of the 112 relationships between the investigated traits. The summary of all analyses conducted is presented in 113 Table 1. First, we examined the effect of body size (childhood and adulthood) on mammographic 114 density (dense area, non-dense area, percent density) using univariable MR and multivariable MR 115 (MVMR) [25]. We then reviewed the role of age at menarche in the childhood body size effect on MD 116 phenotypes. Next, using data from the Breast Cancer Association Consortium (BCAC) [35][36] 117 (Supplementary Table S1), we assessed the effect of MD phenotypes on breast cancer risk. We further 118 investigated pleiotropy among the genetic instruments for the MD phenotypes using a variety of 119 advanced sensitivity analysis methods [37]-[39], PheWAS [40], and pathway analysis, to dissect their 120 heterogeneous effect and improve the understanding of the MD effect on breast cancer. Finally, we 121 performed MVMR of childhood body size and MD phenotypes with breast cancer risk and mediation 122 analysis to assess the direct and indirect effects of both traits and evaluate the role of MD in the poorly 123 understood protective effect of childhood body size on breast cancer.

124

125 This study is reported as per the guidelines for strengthening the reporting of Mendelian randomization

126 studies (STROBE-MR) [41] [42].

127



128

Figure 1. Flow diagram of relationships between traits investigated in this study. Blue arrows indicate a negative (decreasing / protective) effect and pink arrows show a positive (increasing / causal) effect relationship, as previously reported in the literature. The numbers signpost the analysis sections, which are mentioned throughout the text and correspond to the numbers in the analysis summary in Table 1.

- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141 142
- 143
- 144
- 145
- 146
- 140
- 148

perpetuity. It is made available under a CC-BY 4.0 International license .

149 Table 1. Summary of analyses conducted. The table is split into sections (#) for convenient reference throughout the 150 text. Mammographic density (MD) is available as three phenotypes: Dense area (DA), non-dense area (NDA), and 151 percent density (PD); data source: Sieh et al (2020) [32]. Breast cancer outcomes include data from BCAC 2017 and 152 2020 (overall samples, ER+/ER- samples and five molecular subtypes: Luminal A, Luminal B1, Luminal B2, HER2-153 enriched, and triple-negative; summarised in Supplementary Table S1; data sources: [35][36]). Childhood/adult size 154 body and age at menarche data are UK Biobank phenotypes from Richardson et al (2020) [5]. In the table, when several 155 exposures/outcomes are listed (e.g. MD phenotypes or cancer subtypes), this indicates that MR analysis was done 156 separately for each, unless they are two exposures in MVMR. MR - Mendelian randomization, MVMR - multivariable 157 MR. BCAC - Breast Cancer Association Consortium

158

#	Analysis type	Exposure trait(s) represented as genetic instruments	Phenotypic outcome traits(s) (when applicable)	Results available in	
	MR	Childhood body size	Mammographic density (DA, NDA, PD)	Figure 2a,	
1	MR	Adult body size	Mammographic density (DA, NDA, PD)	Table S3	
	MVMR	Childhood body size, Adult body size	Mammographic density (DA, NDA, PD)	Figure 2b, Table S5	
	MR Age at menarche		Mammographic density (DA, NDA, PD)	Figure 2a, Table S7	
2	MVMR	Childhood body size, age at menarche	Mammographic density (DA, NDA, PD)	Figure 2c Table S9	
	MR	Dense area (DA) Breast cancer (overall and subtyp			
3	MR	R Non-dense area (NDA) Breast cancer (overall and subtypes)			
	MR	Percent density (PD)	Breast cancer (overall and subtypes)		
4	MVMR Childhood body size, Dense area (DA)		Breast cancer (overall and subtypes)		
	MVMR	Childhood body size, Non-dense area (NDA)	Breast cancer (overall and subtypes)	Figure 3b, Table S13	
	MVMR	Childhood body size, Percent density (PD)	Breast cancer (overall and subtypes)		
5	MR-PRESSO	Mammographic density (DA, NDA, PD)	Breast cancer overall sample	Figures 4a, S4a, S6a Table S16	
	Radial-MR	Mammographic density (DA, NDA, PD)	Breast cancer overall sample	Figures 4b, S4b, S6b Table S17	
	MR-Clust	Mammographic density (DA, NDA, PD)	Breast cancer overall sample	Figures 4c-d, S4c-d, S6c-d Table S18	
6	PheWAS	Mammographic density (DA, NDA, PD)	N/A	Figure 5, S5, S7 Tables S19-S21	
7	Pathway analysis	Mammographic density (DA, NDA, PD)	N/A	Tables S22-27	
8	Mediation analysis	Childhood body size, Dense area (DA) (as a mediator)	Breast cancer overall sample	Supplementary Note 2	

159

160

161

162 The effect of childhood and adult body size on mammographic density

163

164 We used univariable MR to evaluate the total effect of childhood and adult body sizes on each MD 165 phenotype (analysis #1 in Table 1 and Figure 1). This analysis was performed using MD GWAS data 166 unadjusted for adult BMI to avoid double adjustment for BMI in MVMR analyses; the details of this 167 and subsequent analyses using MD GWAS data adjusted for adult BMI (i.e. the data from the original 168 publication of MD GWAS [32]) are available in Supplementary Note 1. We found evidence that larger 169 body size, both during childhood and as an adult, reduces dense area and percent density, but increases non-dense area (Figure 2a, Supplementary Table S3). The estimates from these analyses 170 171 reflect the standard deviation (SD) change in MD phenotype for each change in childhood and adult body size category. We also performed multivariable MR including both childhood and adult body 172 173 size to estimate the direct effects of body size at each age on MD conditional on the other age (Figure 174 2b, Supplementary Table S5). In this analysis, a direct effect was demonstrated for both traits,

medRxiv preprint doi: https://doi.org/10.1101/2023.09.01.23294765; this version posted September 2, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

175 however, larger childhood body size had a stronger effect on decreasing dense area, while larger 176 adult body size had a stronger effect on increasing non-dense area (adipose tissue area of the 177 breast). The direct effect on percent density was greater from adult body size, but its magnitude was 178 considerably reduced in MVMR for both measures.

179

180 Total effect (MR) b Direct effect (MVMR) С Direct effect (MVMR) Dense area Exposure Von-dense area Childhood body size Adult body size Age at menarche Percent density -1.0 -0.5 0.0 0.5 1.0 -1.0 -0.5 0.0 0.5 1.0 -1.0 -0.5 0.0 0.5 1.0

beta coefficient (1 SD change in MD phenotype per body size category or age SD change)

181

182

183 Figure 2. Univariable MR (total effect) and multivariable MR (direct effect) results of childhood body size, 184 adult body size, and age at menarche effect on MD phenotypes (dense area, non-dense area, percent density) 185 (unadjusted for BMI at GWAS level). (a) Total effect of each exposure on MD outcomes. (b) Direct effects of 186 childhood and adult body sizes on MD outcomes. (c) Direct effects of childhood body size and age at menarche on 187 MD outcomes. The effect is measured as the standard deviation (SD) change in MD phenotype per body size category 188 or age at menarche SD change. Bars indicate 95% confidence intervals around the point estimates from MR/MVMR 189 IVW analyses. The empty circle data points highlight the results where confidence intervals overlap the null.

190 191

192 The effect of childhood body size and age at menarche on mammographic density 193

194 In this MR analysis, we sought to analyse childhood body size and age at menarche together to 195 evaluate their total and direct effects on MD phenotypes (analysis #2 in Table 1 and Figure 1). In 196 univariable MR (Figure 2a, Supplementary Table S7), childhood body size and age at menarche had strong opposing effects on MD (DA and PD), which is in agreement with published studies [20] [21], 197 198 [25]. In MVMR (Figure 2c, Supplementary Table S9) the direct effect of body size conditional on age 199 at menarche is similar to the total effect, while the effect of age at menarche is attenuated to overlap 200 the null. Adiposity in childhood reduces MD and lowers the age at menarche (as shown in [10]), while 201 younger age at menarche has a negative effect on MD (i.e. the inverse of higher age at menarche 202 increasing MD in Figure 2a). The attenuation of age at menarche effect can be explained in the 203 following way: (1) the direct effect of childhood adiposity is maintained in MVMR when accounting 204 for age at menarche, suggesting that adiposity affects MD independently of starting puberty earlier, 205 (2) the menarche effect in univariable results is not present in MVMR results suggesting that it is 206 largely due to unaccounted increased childhood adiposity (and its effect on the initiation of puberty). 207 Collectively, our results show that the density-decreasing effect of larger childhood body size is not 208 acting via lowering the age at menarche, and that childhood body size and age at menarche may 209 have entirely different mechanisms linking them to breast cancer.

210 211

212 The effect of mammographic density on breast cancer

213 214 Next, we evaluated the effect of BMI-unadjusted MD phenotypes on breast cancer (analysis #3 in 215 Table 1 and Figure 1) using IVW MR estimation. The total effect of MD phenotypes on breast cancer 216 subtypes is presented in Figure 3a (Supplementary Table S11). Overall, we found a consistent trend 217 in the direction of effect across all breast cancer subtypes for each MD exposure trait: dense area 218 and percent density increased the risk, while non-dense area decreased the risk, which is in line with 219 the observational data. Despite being consistent, many estimates were imprecise, however, there 220 was stronger evidence for a positive effect of dense area on overall breast cancer, ER+ breast 221 cancer, and several subtypes. The individual SNP-specific effects within all MD phenotypes' total 222 estimates were heterogeneous (detailed below under Sensitivity analysis), and therefore, in the

perpetuity. It is made available under a CC-BY 4.0 International license .

223 **Dissecting the mammographic density effect using robust MR methods** section we explore 224 those effects using various sensitivity and outlier detection methods. The direct effects from the 225 MVMR analysis in Figure 3b are discussed in a later section.

226



Figure 3. (a) The total (univariable MR) and (b) direct (accounted for childhood body size, MVMR) effect of MD phenotypes (unadjusted for BMI) on breast cancer (overall sample from BCAC 2017 and subtype samples). The plots show the odds of breast cancer per SD increment in MD phenotype. Bars indicate 95% confidence intervals around the point estimates from IVW and IVW-MVMR analyses. The empty circle data points highlight the results where confidence intervals overlap the null.

37 Sensitivity analysis

239 To investigate potential violations of the MR assumptions and validate the robustness of the two-240 sample IVW MR results, we performed additional MR analyses using MR-Egger [43] and weighted 241 median [44] approaches, both of which provide sensitivity analyses that are more robust to particular 242 forms of horizontal pleiotropy. The Egger intercept was used to explore the potential for the presence 243 of directional horizontal pleiotropy, and Cochran's Q statistic [45] was calculated to quantify the 244 extent of heterogeneity among SNPs, which is indicative of potential pleiotropy. For MVMR we tested 245 instrument strength, using a conditional F-statistic [46] and examined heterogeneity using an 246 adapted version of the Q-statistic (QA).

247

The estimated total effects of childhood and adult body size measures on MD phenotypes were consistent across MR sensitivity analyses with Egger intercept 0.01 or lower. The F-statistics were > 10 and Q-statistics did not indicate excessive heterogeneity (Supplementary Table S4). In MVMR, the conditional F-statistics were also above 10, indicating that weak instrument bias is unlikely to be present [46]. The presence of directional pleiotropy was assessed by estimating Q_A statistics, which also were not notably large (Supplementary Table S6).

254

The direction of effect was consistent among the MR methods when assessing age at menarche effect on MD phenotypes, but there was less robust evidence of effect in the weighted median result. The F-statistic for age at menarche was above 10; the Egger intercept was substantially close to zero (~0.002), indicating little evidence of directional pleiotropy [47]. The Cochran's Q value was large with p-values <2e-10, indicating high heterogeneity (Supplementary Table S8). In MVMR of age at menarche and childhood body size, the F-statistics were above 10, and Q_A was similar to the Q value in the univariable analysis (Supplementary Table S10).

perpetuity. It is made available under a CC-BY 4.0 International license .

263 In the main IVW analysis of MD phenotypes effect on breast cancer outcomes, the evidence was 264 present only in selected exposure-outcome pairs, as described in the previous section. Applying 265 sensitivity methods to those results showed some inconsistency, with MR-Egger producing imprecise 266 results. The weighted median approach, which relies on at least 50% of the variants' total weight 267 being from valid instruments [44], provided evidence for an effect in substantially more analyses than 268 IVW, which relies on 100% of variants being valid instruments, indicating that some variants may be 269 outliers (Supplementary Table S11). The Egger intercept in the analyses of non-dense area and 270 percent density with subtype outcomes suggested likely presence of horizontal pleiotropy. The 271 intercept in analyses of dense area, where evidence of effect was present in IVW, was smaller, 272 indicating that dense area phenotype is less subject to pleiotropy. The MD phenotypes' instrument 273 strength was good (F-statistics > 10) suggesting that weak instruments are unlikely to be a source 274 of serious bias in the univariable analysis. Steiger filtering did not indicate that MD phenotypes' 275 instruments explained more variance (R²) in breast cancer rather than in MD phenotypes, and 276 therefore, were not excluded from the analysis. Interestingly, we identified substantial heterogeneity 277 for all MD phenotypes, suggested by very high Q-values with small p-values. High heterogeneity 278 may be indicative of one or more variant outliers in the analysis, which was explored with additional 279 sensitivity in the next section. The sensitivity analysis details are available in Supplementary Table 280 S12.

282 Dissecting the mammographic density effect using robust MR methods

283

281

To explore the high heterogeneity in the genetic instruments for the MD phenotypes, we applied several methods that aim to dissect heterogeneity and assess potential horizontal pleiotropy through outlier detection (analysis #5 in Table 1). In this investigation, we focused only on the overall breast cancer sample outcome.

288

289 We used MR-PRESSO [37] and Radial-MR [39] (see Methods) to identify the variant outliers 290 (Supplementary Tables S16-17). For dense area, both methods determined the same set of SNPs 291 as outliers (Figures 4a and 4b). The outlier-corrected total IVW estimates are presented below the 292 single SNP forest plots (outlier SNPs are highlighted), alongside the results of other MR methods. 293 With outliers removed, the point estimate (OR 1.40 [1.26: 1.56]) is similar to the original IVW result 294 (OR 1.38 [1.002: 1.90]), but the confidence intervals are more precise. Consequently, the outlier-295 corrected IVW estimates of dense area had stronger evidence of effect on breast cancer, and were 296 similar to weighted median method results (OR 1.25 [1.12: 1.39]).

297

298 Next, we used MR-Clust [38] to investigate the presence of clustered heterogeneity among the 299 genetic variants. MR-Clust groups genetic variants into clusters with similar estimates for the causal 300 effect of the exposure on the outcome (i.e. based on their direction, magnitude, and precision). A 301 cluster may represent a distinct pathway through which exposure is related to the outcome, and 302 investigating heterogeneous estimates in this way may reveal additional information about the 303 exposure-outcome relationship (see Methods for further details). MR-Clust detected three distinct 304 clusters ('cluster 1', 'cluster 2', 'cluster 3'), a 'null' cluster, and two 'junk' SNPs that were not 305 assigned to any of the clusters (Figure 4c, Supplementary Table S18). We see that the heterogeneity 306 outliers flagged by MR-PRESSO and Radial-MR (Figures 4a and 4b) represent separate clusters in MR-Clust (Figure 4d). 'Cluster_2' (blue) is equivalent to the outlier-corrected estimate from those 307 308 earlier analyses and the variants in this cluster are positively associated with an increase in both 309 dense area and breast cancer risk. 'Cluster_3' (orange) and a positive 'junk' SNP are associated 310 with breast cancer to a higher magnitude (Figure 4c) and therefore form a separate cluster. 311 Interestingly, the SNPs in 'cluster_1' are protective of breast cancer despite being associated with 312 increased density. It is important to note that both the inverse association ('cluster_1') and the same 313 direction but higher magnitude association ('cluster_3') clusters add to the overall heterogeneity of 314 the total estimate.

315

The results for non-dense area and percent density phenotypes are presented in Supplementary Figures S4 and S6. We similarly found outliers and clusters in those traits' instruments. However,

- 318 due to the lower number of instruments available for these traits, the results from MR-PRESSO and
- 319 Radial-MR should not be overinterpreted. The outlier-corrected IVW estimates (non-dense area -

medRxiv preprint doi: https://doi.org/10.1101/2023.09.01.23294765; this version posted September 2, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

320 OR 0.75 [0.65: 0.86] and percent density – OR 1.29 [1.16: 1.44]) were similar to the weighted median method results (OR 0.74 [0.63: 0.87] and OR 1.32 [1.14: 1.53], respectively) (Supplementary Tables 321 S16 and S17). In MR-Clust, for non-dense area and percent density, there were also variants that 322 323 associated with breast cancer in the opposite direction to the overall and expected effect from the 324 exposure (e.g. negatively associated with breast cancer risk but positively associated with a factor 325 causal for breast cancer, or vice versa) - two 'negative effect' outliers for percent density and one 326 'positive effect' outlier for non-dense area).







Figure 4. Exploring the heterogeneity of genetic instruments of dense area phenotype on overall breast cancer (BCAC 2017). (a) Single SNP forest plot (Wald Ratio estimates), with SNPs identified as outliers by MR-PRESSO marked in blue. The outlier corrected estimate is presented along with the standard MR methods estimates. (b) Single SNP forest plot with SNPs identified as outliers by Radial-MR marked in yellow. The outlier corrected 334 estimate is presented along with the standard MR methods estimates. (c) MR-Clust scatter plot showing genetic 335 association with dense area and breast cancer per SD change in dense area. Each genetic variant is represented by 336 a point. Error bars are 95% confidence intervals of the Wald Ratio for each variant. Colours represent the clusters. 337 and dotted lines represent the cluster means, the point size denotes cluster inclusion probability. The "null" cluster, 338 coloured pink, relates to variants with null effect, whilst the black "junk" cluster are variants that were not assigned to 339 any cluster. The error bars denote the standard error estimates of the Wald Ratio for each instrumental variable. (d) 340 Single SNP forest plot with SNPs coloured by the cluster membership assigned by MR-Clust (using the same colours 341 as in the scatter plot). The IVW MR estimates for each cluster are presented below single SNP estimates. IVW -342 inverse-variance weighted; MRE - multiplicative random effects

perpetuity. It is made available under a CC-BY 4.0 International license .

343 PheWAS

344

345 We carried out a phenome-wide association study (PheWAS) analysis [40] on the genetic 346 instruments for the MD phenotypes to examine their associations with other traits (analysis #6 in 347 Table 1). We aimed to review the differences between associations by clusters identified with MR-348 Clust and evaluate whether outlier SNPs may be strongly associated with other phenotypes, which 349 may explain the horizontal pleiotropic effect and hint at alternative causal pathways for those outliers. 350

351 The PheWAS results for the dense area phenotype are plotted in Figure 5. The SNPs that were 352 identified as outliers in previous analyses and that formed distinct clusters from the main effect 353 clusters, have a higher number of associations with other traits, highlighting their pleiotropic effect. 354 In the plot, we use the diamond shape to indicate dense area SNPs that associate strongly (p-value 355 < 5e-08) with breast cancer. Those SNPs correspond to 'cluster_3', 'cluster_1', and 'junk' cluster 356 SNPs in the MR-Clust results, here similarly flagging their association with breast cancer risk, which 357 may be happening via a different pathway other than through dense area.

358

370

359 PheWAS plots for non-dense area and percent density are available in Supplementary Figures S5 360 and S7. For those phenotypes, similarly, we found associations with breast cancer for the outlier 361 SNPs. All found associations are available in Supplementary Tables S19-21. 362



363 364 Figure 5. PheWAS results for dense area phenotype genetic variants, ordered by SNP effect and cluster 365 membership (from MR-Clust). The data points are other traits associated with dense area SNPs (y-axis) at p-value 366 <5e-08 (x-axis, -log10 scale, capped at value 50). The colour shows the cluster membership, in the same palette 367 and order as in Figures 4c/4d. Data points represented by solid 'diamond' shapes are breast cancer outcomes; 368 'plus' shapes are all other traits. 369

371 Gene and pathway overview

372 373 To gain some biological context for the identified outlier SNPs and distinct clusters, we mapped 374 instrument SNPs to genes (Supplementary Tables S22-24; see gene-labelled forest plots in 375 Supplementary Figure 8) and identified pathways that those genes are involved in (analysis #7 in 376 Table 1). Performing a formal gene-set enrichment analysis was not possible here due to the limited 377 number of SNPs available for each phenotype/cluster. Therefore, instead, we created a simple 378 overview of pathway sets that came up for genes in positive and negative effect clusters 379 (Supplementary Table S25-27, Supplementary Figure 9). 380

381 For dense area, we found a number of unique pathways that only appeared in genes/SNPs with a 382 negative effect. Among those genes, most were described in the functional analyses of previously 383 published MD GWAS [48], [49], [32], such as MKL1/MRTFA (rs73169097 – negative 'null' cluster 384 SNP) and MTMR11 (rs11205303), both of which have dense phenotype-increasing effect but are 385 protective against breast cancer. The potential tumour-inhibiting and tumour-promoting role of MKL1

perpetuity. It is made available under a CC-BY 4.0 International license .

386 was previously acknowledged in [48]. MTMR11 is negatively associated with both dense area and 387 percent density (but as a result of LD clumping it is an instrument only for dense area). It appears to 388 be involved in phosphoinositides/phosphatidylinositol metabolism pathways, which are also 389 implicated in cancer. For percent density, the genes in negative clusters were also previously 390 described in published functional analyses - OTUD7B (rs12048493) and ZNF703 (rs4286946) [49], 391 [50]. Interestingly, the positive outlier in non-dense area instruments is also mapped to ZNF703 392 (rs75772194), which is also associated with breast size. The complete overview of 393 cluster/genes/pathways is available in Supplementary Tables S25-27.

394 395

396 The direct effect of mammographic density and childhood body size on breast cancer 397 risk

398

399 In the earlier sections, we reviewed the total effect of MD phenotypes on breast cancer risk (Figure 400 3a) and explored it using various sensitivity analyses. In this section, we dissect the direct effects of 401 childhood body size and MD phenotypes on breast cancer risk using MVMR (analysis #4 in Table 1 402 and Figure 1). In Figure 3b (Supplementary Table S13), we see the direct effect of MD on breast 403 cancer accounting for childhood body size, presented alongside the total effect for comparison. 404 There is evidence of a positive direct effect from the dense area on all breast cancer subtypes. The 405 point estimates are similar to those of the total effect, but with more precise confidence intervals. 406 There is evidence of a negative effect from non-dense area on Luminal B1 and triple-negative 407 subtypes, while the effects on other samples have been further attenuated towards the null. For 408 percent density, the magnitude of effect and the uncertainty around the point estimate is reduced in 409 MVMR analysis, with little evidence for an effect of PD on all breast cancer subtypes when 410 accounting for childhood body size. It should be noted that IVW MVMR estimates may also be 411 potentially biased by pleiotropy in the same way as total effect estimates in univariable MR.

412

413 From the same MVMR analysis as the results in Figure 3b, we have also estimated the direct effect 414 of childhood body size on breast cancer accounted for MD phenotypes. Figure 6 presents the total 415 effect of childhood body size on breast cancer (overall and subtypes) (Supplementary Table S15) 416 along with the direct effect accounted for each MD phenotype (Supplementary Table S13). The total 417 effect is strongly protective against all outcomes. In previous work, this protective effect was not 418 disrupted by accounting for any hypothesised mediators [10]. In this analysis, we see that accounting 419 for MD phenotypes attenuates the protective effect making the confidence intervals overlap the null, 420 suggesting that MD may have a role in partially explaining it. When accounting for the dense area, 421 the effect attenuation is seen for all outcomes except the ER- sample. For percent density, the effect 422 on breast subtypes is attenuated but to a lesser extent, which may suggest that dense area 423 phenotype has a stronger mediating role than percent density. For non-dense area, the effect is 424 attenuated also on a subset of breast cancer subtypes. Interestingly, the effect on ER- subtype is 425 the least affected, suggesting there might be some difference in how MD affects ER- breast cancer 426 risk. 427

428 It is important to note that the number of MD instruments in this MVMR analysis was limited 429 (Supplementary Table S2). These MVMR results are also affected by weak instrument bias, as F-430 statistics are low in these analyses: childhood body size and dense area (F-stat, 17 and 7, 431 respectively) non-dense area (6 and 3), percent density (7 and 4), respectively (Supplementary Table 432 S14).

- 433
- 434
- 435

perpetuity. It is made available under a CC-BY 4.0 International license .



436 437

Figure 6. The total and direct effects of childhood body size (accounted for MD phenotypes – dense area, non-dense area, percent density (unadjusted for BMI at GWAS level)) on breast cancer (overall sample from BCAC 2017 and subtype samples). The plots show the odds of breast cancer per body size category change. Bars indicate 95% confidence intervals around the point estimates from IVW and IVW-MVMR analyses. The empty circle data points highlight the results where confidence intervals overlap the null.

442 443

444 Mediation analysis

445

446 We performed mediation analysis using MR and MVMR results to assess the role of mammographic 447 density (specifically, dense area) in the relationship between childhood body size and breast cancer.

447 density (specifically, dense area) in the relationship between childhood body size and breast cancer.
448 This investigation was also done focussing only on the overall breast cancer sample (analysis #8 in
449 Table 1).

450

We estimated the indirect effect via MD, using both Product and Difference methods for mediation analysis (see **Methods**). Both methods produced similar indirect point estimates in the same direction, -0.23 [95% CIs; -0.33: -0.13] and -0.22 [-0.48: 0:05], respectively. The proportion of the mediated effect via dense area using the Product method estimate was 0.56, indicating that dense area may account for 56% [32%-79%] of the childhood body size protective effect on breast cancer (see **Supplementary Note 2** for mediation analysis calculations).

11

457 458

- 459
- 460

- 462 463
- 464
- 465
- 400
- 466
- 467 468

perpetuity. It is made available under a CC-BY 4.0 International license .

469 **Discussion**

470

471 The protective effect of higher childhood adiposity on breast cancer risk has been reported in both 472 observational and MR studies [3]-[7]. However, the mechanism behind this effect has been 473 challenging to decipher, even after reviewing nearly 20 potential mediators [10]. A few observational 474 studies have suggested that mammographic density may have a role in this relationship [28]-[31]. 475 In this study, we explored the mediating role of MD in the protective effect of higher childhood 476 adiposity on breast cancer risk using Mendelian randomization, examining the complex relationships 477 between childhood body size, adult body size, age at menarche, mammographic density, and breast 478 cancer risk.

479

480 Firstly, we investigated the factors that may affect MD – adiposity at different life stages and age at 481 menarche. We found that higher childhood and higher adulthood adiposity decrease dense area and 482 percent density, while both increase the non-dense (adipose tissue) area. In multivariable MR 483 analysis, however, the independent direct effect of childhood adiposity was stronger for decreasing 484 dense area, while adult adiposity was stronger for increasing non-dense area. The inverse effect of 485 higher body size on density is likely explained by increasing breast adiposity, reducing the proportion 486 of fibroglandular components, and increasing adipocyte differentiation of stromal cells, thus reducing 487 collagen production [51]. As breast tissue undergoes substantial development during puberty, it is 488 reasonable that childhood rather than adult adiposity is a more important factor for dense area. The 489 stronger effect of adult adiposity on the non-dense area is likewise logical, as the change in MD with 490 age is reflected in glandular tissue reduction and an increase in fat [52]. We also showed that 491 adjustment for BMI in GWAS may lead to an unexpected and misleading result in MR analysis 492 (Supplementary Note 1), if BMI (i.e. heritable covariate) also has a role in the studied relationship 493 [53] [54].

494

495 The previously observed association of age at menarche with breast density [20] was replicated in 496 our MR analysis, with later menarche increasing dense area and percent density and decreasing 497 non-dense area. In MVMR with childhood body size, however, the effect of age at menarche on MD 498 phenotypes was attenuated. Greater adiposity in childhood reduces dense area and percent density 499 and lowers the age at menarche [10], while earlier menarche decreases dense area and percent 500 density. Therefore, the attenuation of its effect in MVMR indicates that the menarche effect observed 501 in the univariable analysis may be due in part to increased adiposity (and its effect on the initiation 502 of puberty). Collectively, our results suggest that the density-decreasing effect of childhood body size 503 is not acting predominantly via lowering the age at menarche.

504

505 This finding draws attention to prior MR studies showing little evidence of effect of age at menarche 506 on breast cancer risk [10], [55]. Interestingly, in MVMR analyses when accounting for BMI, there is 507 a shift from the neutral effect to a causal effect with earlier age at menarche increasing the risk. It 508 is likely that the total effect of age at menarche is driven (and disguised) by childhood BMI SNPs 509 in the age at menarche GWAS instruments, and accounting for BMI in MVMR separates the 510 independent effects of childhood BMI and age at menarche on breast cancer risk. Taken together 511 with our finding that MD is not affected by age at menarche when accounting for body size, this 512 suggests that the mechanisms linking childhood adiposity and age at menarche to breast cancer 513 could be entirely different and operate in opposite directions. Uncovering the mechanistic links in 514 both relationships (as partly done in this work with respect to childhood body size) will identify 515 different pathways that could be modifiable, and together could contribute a very substantial 516 component of modifiable breast cancer risk. Another important consideration relating to 517 mechanistic links is the distinction between mutagenesis and promoters in breast cancer causation 518 [56], which may also contribute to the differential effects of childhood adiposity and age at 519 menarche on breast cancer risk.

520

521 The central relationship explored in our study is that of MD and breast cancer, and whether MD helps 522 explain the inverse association of childhood adiposity and breast cancer risk. When examining the 523 total effect of MD phenotypes on breast cancer risk (overall and subtypes), we observed consistent 524 trends in the direction of effects, with dense area and percent density increasing the risk and non-525 dense area decreasing the risk, in line with observational results [12][13]. We found evidence of a

perpetuity. It is made available under a CC-BY 4.0 International license .

526 positive effect from the dense area on breast cancer risk overall and for certain subtypes, but for 527 other MD exposure/breast cancer outcome pairs the evidence was insufficient. The results produced 528 by the IVW method may potentially be biased by pleiotropy, therefore the detected high levels of 529 heterogeneity were further explored in our analysis and will be discussed below. It is also worth 530 mentioning that our results may slightly differ from the previously published MR results using related 531 data [10], [32], [33], which could be explained by the differences in the MR methods employed, the 532 approach to instrument selection, and the fact that the MD GWAS was unadjusted for BMI in this 533 study.

534

535 While the total effect of MD on breast cancer was imprecisely estimated, IVW-MVMR of MD 536 phenotypes with childhood body size showed strong evidence of a risk-increasing direct effect from 537 the dense area on all breast cancer subtypes, with less evidence for a negative effect of non-dense 538 area and a lack of evidence for an effect of percent density. This highlighted the possibility that dense 539 area is the more important risk factor for breast cancer, however in observational studies [12], 540 percent density has been found to have a stronger association because it combines the effects of 541 both dense area and non-dense area which have distinct genetic aetiologies [32]. The direct effect 542 of childhood body size on breast cancer was attenuated in this MVMR analysis, suggesting a 543 potential mediating role of mammographic density in the relationship between them. This is the first 544 time we have observed an attenuation of the effect of childhood body size; in our previous work, 545 where many potential mediations were assessed, the body size effect remained unaffected [10]. 546 Interestingly, this attenuation of effect was not present in analyses of ER-negative breast cancer, 547 suggesting that there might be some differences in how MD affects this disease subtype. We 548 considered including adult body size and age at menarche as covariates in MVMR, however, we 549 opted not to pursue this analysis due to concerns about the statistical power. 550

551 In addition to the effect changes observed in MVMR, we conducted a formal mediation analysis with 552 the dense area phenotype. Both mediation methods we applied produced very similar indirect effect 553 estimates (-0.23 and -0.22, Product and Difference methods, respectively). Such agreement of 554 estimates was not the case for other mediators we reviewed in our previous work [10]. The 555 confidence intervals around these estimates were more precise for the Product method -0.23 [-0.33: 556 -0.13]). The calculated proportion mediated via dense area suggested that 56% [32%-79%] of 557 childhood adiposity's protective effect could be due to it decreasing the dense area in childhood, 558 which leads to reduced breast cancer risk in adulthood.

559

560 The above finding is promising, however, the relationship of MD phenotypes with breast cancer is 561 complex and, as shown in our sensitivity analyses, the genetic variants used in the analysis have 562 heterogeneous estimates and are potentially highly pleiotropic. We thoroughly evaluated the dense 563 area, non-dense area, and percent density genetic instruments using several robust MR outlier 564 detection methods and an MR clustering method, MR-Clust, to decompose heterogeneity in the 565 results. For dense area and percent density, we found a set of outlier SNPs that together formed 566 'negative effect' clusters, which mapped to genes that were associated with higher dense 567 area/percent density, but a decreased cancer risk. This has been previously reported for the same 568 identified genes, e.g. MLK1 in [48] and MTMR11 in [49]. Similarly, for the non-dense area, we found 569 one SNP with the opposite effect on breast cancer to the overall effect direction. The PheWAS 570 analysis highlighted the fact that outlier SNPs, which also form separate clusters of MD effect on 571 breast cancer, were highly pleiotropic, with the majority also associated with breast cancer. Several 572 methods for outlier correction showed that removing those SNPs results in stronger and more 573 consistent effects of MD phenotypes on breast cancer risk.

574

575 The discovery of multiple MD variants that are also breast cancer susceptibility loci, highlights their 576 shared genetic component and the critical role MD plays as an intermediate phenotype for the 577 disease. The inconsistency in the direction of associations between some MD-associated SNPs and 578 breast cancer risk is perplexing, and is the reason for the observed heterogeneity in MR estimates. 579 One potential explanation for discrepancies in these variants may be that multiple alternative 580 pathways are involved, and are acting across different life stages, which differentially affect breast 581 development and the risk of breast cancer. There is also a strong possibility that not all contributors 582 to MD influence breast cancer risk. Understanding, and correctly classifying the driving components

perpetuity. It is made available under a CC-BY 4.0 International license .

of MD (reviewed in [57]) into those that influence breast cancer risk, and using those for future studies could increase results precision and the degree of mediation detected. Motivated by a recent study that explored a similarly heterogenous effect of IGF-1 on type 2 diabetes using MR-Clust and pathway analysis [58], in our work, we attempted to characterise pathways that may be underlying the identified positive and negative effect clusters. In our case, however, due to the limited number of instruments, pathway gene-set enrichment analysis was not feasible. An extensive pathway analysis based on the MD GWAS used in our work was reported in the original publication [32].

591 The limitations of our study, including the precision of estimates and pathway analysis, can be 592 attributed to the small sample size of the currently available MD GWAS data and the consequent low 593 number of robustly associated genetic instruments. Despite using one of the largest MD GWAS 594 cohorts to date (N=24,192) [32], the number of instruments was still relatively small (albeit higher 595 than in earlier studies, such as [48], [59]). A summary table of all published MD GWAS studies is 596 provided in a recent review [60]. A similarly sized MD GWAS conducted on data from the BCAC 597 cohort (N=24,579-27,900) [61] has recently been released, but due to the unavailability of effect 598 sizes, it is not possible to validate our findings using this resource. Once larger MD GWAS studies 599 become available, and more SNPs with robust associations are identified, our results could be 600 replicated. A higher number of instruments would also enable more informative clustering and 601 pathway analyses, despite the likely maintained heterogeneity amongst individual estimates. 602 Furthermore, the estimation of childhood body size indirect effect via MD would also likely be more 603 precise.

604

605 It is important to highlight a few recent developments in studying the genetics of mammographic 606 density. Firstly, the first-ever GWAS of breast tissue structure patterns (also referred to as texture 607 features) has recently been published [62], which is an emerging independent breast cancer risk 608 factor [63]. Texture variation can differ substantially between women, despite having the same 609 percent density. Including this trait in the MD phenotype analyses (including MR) can produce 610 additional insights into the development of breast cancer. Secondly, as exploring proximal molecular 611 mediators is becoming more widespread, the analysis of MD phenotypes in the BCAC cohort [61] 612 also included a transcriptome-wide association study (TWAS). The study revealed additional novel 613 associations between imputed breast tissue expression level and MD phenotypes. Some of the 614 identified genes were located in proximity to GWAS loci, suggesting the observed genotype-615 phenotype association for MD may be mediated through gene expression. Further, a recent 616 transcriptomic study [64] evaluating differentially expressed pathways in breast tissue samples from 617 obese vs normal weight adolescents, identified inflammation-related genes as among the most highly 618 activated upstream regulators in the obese breast tissue samples.

619

620 Our study thoroughly explores the links between adiposity, puberty timing, and mammographic 621 density, and breast cancer. The major finding of this study is that mammographic density, specifically 622 dense area, potentially accounts for 56% of the protective effect of childhood adiposity on breast 623 cancer. Understanding this mediating pathway is crucial since simply advocating for weight gain in 624 childhood is clearly not a desirable goal. This finding is exciting because showing that adult MD is 625 modifiable during the pubertal growth period means there could be opportunities to intervene during 626 adolescence to reduce lifetime MD and associated breast cancer risk [18]. Further understanding of 627 the underlying mechanism and biological pathways is required to explore potential avenues for 628 intervention. In the study, we also showed that the density-increasing effect of later menarche may 629 be due to lower adiposity in adolescence, which is associated with later puberty rather than an effect 630 of age at menarche directly. The mechanisms linking childhood body size and age at menarche to 631 breast cancer risk could therefore be entirely different and acting in opposing directions. Lastly, we 632 found that genetic instruments for MD are heterogenous and pleiotropic, and there are likely several 633 pathways underlying the role of mammographic density in influencing breast cancer risk. As MD 634 GWAS sample sizes increase, this relationship can be further investigated, enhancing our 635 understanding of the genetic basis of MD and its role in the aetiology of breast cancer. 636

637

007

perpetuity. It is made available under a CC-BY 4.0 International license .

639 Methods

640

641 Data sources

642

643 The mammographic density GWAS data used in this study is a meta-analysis of two studies (Hologic 644 study, N=20,311 and GE study, N=3881; in total N=24,192) of non-Hispanic white women aged 645 between 40-74 years from a larger population-based study, RPGEH (Research Program on Genes, 646 Environment and Health), administered by Kaiser Permanente Northern California (KPNC) Division 647 of Research [65], [66]. The cohort details and study design have been described previously in the 648 original publication of this data [32]. Genotypes were re-imputed with an expanded reference panel, 649 including the Haplotype Reference Consortium in addition to the 1000 Genomes Project Phase III 650 data, to improve accuracy for less common variants. The GWAS analyses were adjusted for age at 651 mammogram, BMI, genotype reagent kit, and the first ten principal components of ancestry as 652 described previously [32]. Three mammographic density phenotypes were analysed: dense area 653 (DA), non-dense area (NDA), and percent density (PD). The original MD GWAS published by Sieh 654 et al in 2020 [32] was adjusted for BMI. For this study, the GWAS was rerun without this adjustment 655 ("unadjusted GWAS") on a slightly smaller subset of 24,158 women from the original cohort. 656

657 Childhood body size, adult body size, and age at menarche data used in this study were obtained 658 from UK Biobank [67]. UK Biobank is a population-based health research resource consisting of 659 approximately 500,000 people, aged between 40-69 years, who were recruited between the years 660 2006 and 2010 from across the UK. The study design, participants and quality control (QC) methods 661 have been described in detail previously [67]. The GWAS of childhood body size and adult body size 662 used in this study were performed by Richardson et al [5] on UK Biobank data (N= 246,511; female-663 only data). Childhood body size is a categorical trait describing body size at age 10, with three 664 categories ('thinner than average', 'about average', 'plumper than average'), from a questionnaire 665 completed by adult participants of UK Biobank. Adult body size measure was converted from 666 continuous adult BMI in UK biobank into three groups based on the proportions of childhood body 667 size data to ensure that the GWAS results of both measures are comparable [5]. The genetic scores 668 for childhood and adult body size were independently validated in three separate cohorts (the HUNT 669 study (Norway) [68], Young Finns Study [69], and ALSPAC (UK) [5]), which confirmed that the 670 genetic instruments extracted by Richardson et al [5] can reliably separate childhood and adult body 671 size as distinct exposures, in addition to being robust to differential measurement error in simulations 672 performed in the original study. Age at menarche GWAS summary data (N=143,819) was accessed 673 through OpenGWAS [70] (gwas.mrcieu.ac.uk) under ID ukb-b-3768.

674

675 The breast cancer data used in the study is from the Breast Cancer Association Consortium (BCAC) 676 cohort of 2017 (N=228,951; overall sample and ER+/ER- samples, assessed from OpenGWAS 677 under IDs: ieu-a-1126, ieu-a-1127, ieu-a-1128) [35] and the latest release of BCAC in 2020 678 (N=247,173; overall sample and five molecular subtypes: Luminal A, Luminal B1, Luminal B2, HER2-679 enriched, and triple-negative breast cancer) [71] (details in Supplementary Table S1). The cohort 680 described design and genotyping protocol details are elsewhere 681 (bcac.ccge.medschl.cam.ac.uk/bcac-groups/study-groups/,

bcac.ccge.medschl.cam.ac.uk/bcacdata/). The study groups in the BCAC cohort do not include UK
 Biobank or MD GWAS cohorts. The overall sample results presented throughout the paper are for
 BCAC 2017 data. The results for BCAC 2020 overall sample are available in all relevant
 Supplementary tables, and are not shown here due to their similarity.

686 687

688 Mendelian randomization

689 690 Mendelian randomization (MR) is an application of instrumental variable analysis where genetic 691 variants are used as instruments to estimate the causal relationship between a modifiable health 692 exposure and a disease outcome [8] [9]. There are three core assumptions that genetic variants 693 need to satisfy to qualify as valid instruments for the causal inference: (1) variants have to be reliably 694 associated with exposure of interest, (2) there cannot be any confounders of the instrument and the

perpetuity. It is made available under a CC-BY 4.0 International license .

695 outcome, and (3) variants cannot be independently associated with the outcome, via pathway other 696 than through the exposure (i.e. horizontal pleiotropy) [72].

697

698 The analyses in this work were performed using the two-sample (univariable) MR approach, which 699 relies on using GWAS summary statistics of two non-overlapping samples for exposure and outcome 700 [73]. Two-sample MR analyses were performed using the inverse-variance weighted (IVW) method 701 [74]. Alongside IVW, other complementary MR methods were applied to assess the robustness of 702 the causal estimates and to overcome any potential violations of the MR assumptions (e.g. horizontal 703 pleiotropy) (see Sensitivity analysis for further details).

704

705 We used the two-step MR framework to assess whether an intermediate trait acts as a causal 706 mediator between the exposure and the outcome of interest [75], [76]. Multivariable Mendelian 707 randomization (MVMR) was used to estimate the independent direct effects of two traits together on 708 the outcome [77] [78]. The genetic variants included in MVMR analysis have to be reliably associated 709 with one or both exposures but not completely overlap (i.e. no perfect collinearity), and have to satisfy 710 the MVMR-extended second and third assumptions of the standard MR analysis [46]. Diagnostic 711 methods and sensitivity tests for the robustness of MVMR estimates [46] [79] are described under 712 Sensitivity analysis.

713

714 All analyses were conducted using R (v4.2.1). Univariable MR analyses and sensitivity tests were 715 performed using the TwoSampleMR R package (v0.5.6) [80], which was also used for accessing 716 GWAS summary data deposited in OpenGWAS [70] (gwas.mrcieu.ac.uk). Multivariable MR was 717 carried out using the MVMR R package (version 0.2) [77].

718

719 For all exposure traits, the instruments were extracted by selecting SNPs with p-value under the 720 $5x10^{-8}$ threshold and clumping the resulting set of variants with r2 = 0.001 using the default LD 721 (linkage disequilibrium) reference panel in TwoSampleMR (1000 Genomes Project, European data 722 only). When extracting instruments from the outcome (breast cancer) GWAS summary statistics, 723 unavailable SNPs were substituted by proxies with a minimum LD $r^2 = 0.8$. The rest of the settings 724 were kept to defaults as per the package version number. The number of instruments used in the 725 analysis for all exposures: childhood body size (115), adult body size (173), age at menarche (190), 726 dense area (21), non-dense area (8), percent density (11). 727

728 Sensitivity analysis

729

730 In addition to the standard MR analysis (IVW), we used MR-Egger [43] and weighted median [44] 731 MR methods to evaluate the validity of the analysed genetic instruments and to overcome and accommodate potential violations of the core MR assumptions. These complementary methods help 732 733 to support the causal effects found with IVW, as a single method cannot account for all biological 734 and statistical properties that may impact MR estimates. Also a variety of specialised tests were 735 applied, as recommended in [80].

736

737 To assess overall horizontal pleiotropy (violation of assumption 3), the intercept in the MR-Egger 738 regression [43] was evaluated, and the heterogeneity among the genetic variants was quantified 739 using Cochran's Q-statistic [45]. The intercept term in MR-Egger regression is a useful indication of 740 whether directional horizontal pleiotropy is driving the results of an MR analysis, under the 741 assumption that any pleiotropic effects are uncorrelated with the magnitude of the SNP exposure 742 association. When the Egger intercept is close to zero (e.g. < 0.002) and the P-value is large, this 743 can be interpreted as no evidence of a substantial directional (horizontal) pleiotropic effect.

744

745 When the Q-statistic for heterogeneity (difference in individual ratio estimates) is high and the 746 corresponding p-value is small, this suggests evidence for heterogeneity and possibly horizontal 747 pleiotropy. A high Q-statistic can also be used as an indicator of one or more variant outliers in the 748 analysis, which may also violate the MR assumptions. In univariable MR, heterogeneity may be 749 indicative of horizontal pleiotropy that does not act through one of the exposures. In MVMR, 750 heterogeneity is quantified by QA-statistic (also a further modification of Cochran's Q), and small QA 751 indicates a lack of heterogeneity in the per-SNP effects [46].

perpetuity. It is made available under a CC-BY 4.0 International license .

752

753 We derived F-statistics in both univariable and MVMR to evaluate the instrument strength [81] [46], 754 with F > 10 indicating sufficient strength for minimal weak instrument bias in the analysis. We also 755 evaluated the possibility of reverse causation via Steiger filtering and assessed whether each instrument explains more variance (R^2) in the exposure rather than in the outcome [82]. 756

757 758

759 Additional sensitivity and outlier analyses

760

761 To explore the excessive heterogeneity and potential pleiotropy identified in the effect of MD on breast cancer, we explored the genetic instruments using several outlier detection methods. 762

763

764 First, we applied MR-PRESSO [37], a method that detects overall pleiotropic bias through outlier 765 detection by assessing each genetic variant's contribution to the overall heterogeneity. This method 766 discards influential outliers from the IVW method and uses a distortion test to evaluate the 767 significance of the distortion between the causal estimate before and after the removal of the outlier 768 variants, providing an outlier-corrected pleiotropy-robust causal estimate as a result. The analysis 769 was run using the MR-PRESSO R package (v1.0), using the default parameters. 770

771 We also used the approach implemented in *Radial-MR* [39] (R package v1.0) to identify outliers with 772 the most weight in the MR analysis and the largest contribution to Cochran's Q statistic for 773 heterogeneity. The analysis was conducted with a p-value threshold (alpha parameter) set to 774 Bonferroni corrected for the number of SNPs tested in the analysis (p < 0.05/number of instruments 775 in the exposure) and using modified second-order weights (weight parameter).

776

777 Finally, to investigate the presence of clustered heterogeneity and assess the possibility of there 778 being several distinct causal mechanisms by which MD may influence breast cancer risk, we 779 performed clustered Mendelian randomization using MR-Clust [38] (R package v0.1.0). MR-Clust is 780 a heterogeneity-based clustering algorithm that extends the typical MR assumption that a risk factor 781 can influence an outcome via a single causal mechanism [83] to a framework that allows one or more 782 mechanisms to be detected. The heterogeneity and outliers in the main MR result may indicate that 783 different genetic variants influence the risk factor in distinct ways, e.g., via distinct biological 784 mechanisms.

785

786 MR-Clust assigns variants to K clusters, where all variants have similar causal ratio estimates, a 787 "null" cluster (variants with a null effect), and a "junk" cluster (non-null variants that do not fit into any 788 of the K clusters). In our analysis, the clusters were formed of variants that had a great conditional 789 probability of assignment (score > 0.9), keeping the results conservative. Due to the limited number 790 of instruments in MD exposure, we kept all clusters regardless of their size (visualised using the MR-791 Clust package built-in scatter plot).

792

793 The outliers identified by MR-PRESSO and Radial-MR analyses, as well as clusters of SNPs 794 detected by MR-Clust, were displayed using single-SNP forest plots to explore individual SNPs 795 heterogeneity. The single-SNP forest plots show the effect of the exposure on the outcome for each 796 SNP separately (i.e. Wald ratio). The plots also included the IVW MR estimate with the identified 797 outliers excluded, and the invididual estimates for identified clusters. 798

799 **PheWAS**

800

801 To further examine the genetic instruments of the MD phenotypes and better understand the 802 potential sources of effect heterogeneity, we performed a phenome-wide association study 803 (PheWAS) analysis [40]. We used PhenoScanner V2 (phenoscanner R package v1.0) [84] [85] and 804 OpenGWAS database (gwas.mrcieu.ac.uk/phewas/, accessed via ieugwasr R package v0.1.5) [70] 805 to query publicly available GWAS data for associations with the SNPs from the MD phenotypes. The 806 query was restricted to European ancestry datasets, retrieving SNP-trait associations of p-value <5e-807 08. 808

perpetuity. It is made available under a CC-BY 4.0 International license .

809 We presented PheWAS results for each MD SNP grouped by clusters determined by the MR-Clust 810 algorithm. This helped us to review the association differences between clusters of SNPs with the 811 traits identified in GWAS databases, which might explain some of the observed heterogeneity in the 812 MR results.

813 814

815 **Gene and pathway exploration** 816

817 To explore the functional relevance of the identified clusters of MD instruments, we mapped 818 instrument SNPs of each MD phenotype to genes and identified the pathways thay are involved in. 819 For gene mapping we used the SNP2Gene function of FUMA (the Functional Mapping and 820 Annotation of GWAS) platform [86], where we used a 500-kb positional map, and included genes 821 whose expression was associated with the locus in GTEx v8 (breast or adipose tissues). We 822 extracted pathways using the enrichR R package (v3.1) [87] (including pathway definitions from 823 KEGG, GO terms, and WikiPathway databases). We also Reactome. used the 824 ReactomeContentService4R R package (v1.4.0) [88] to obtain more recent Reactome data 825 (Reactome data in enrichR is only up until 2016). The pathway data was collected for a broader 826 context only, and no formal gene-set overrepresentation analysis was performed.

827 828

829 Mediation analysis

830

831 Mediation analysis is used to quantify the effects of an exposure on an outcome, which act directly 832 or indirectly via an intermediate variable (i.e., mediator) [89]. Identifying mediators of the relationship 833 between the exposure and the outcome enables intervention on those mediators to mitigate or 834 strengthen the effects of the exposure [34].

835

The total effect of exposure on outcome includes both a direct effect and any indirect effects via one or more mediators. The total effect is captured by a standard univariable MR analysis. To decompose direct and indirect effects, we used the results from two-step MR and MVMR in two mediation analysis methods: Difference method and Product method.

840

841 For the Difference method, to estimate the indirect effect, we subtracted the direct effect of exposure 842 on the outcome from MVMR (in analysis with the mediator) from the total effect of exposure on the 843 outcome (univariable MR) [55]. In Product method (also known as 'product of coefficients'), the 844 results from two steps of two-step MR analysis (i.e., the effect of exposure on the mediator and the 845 effect of the mediator on the outcome) are multiplied to get the indirect effect [90], [75]. Here, we 846 used the direct effect of the mediator on the outcome from MVMR as the second term in the 847 calculation [89]. To estimate the standard error (SE) and later confidence intervals (CIs) of the 848 indirect effect, we used 'Propagation of errors' approach for the Difference method estimate (as 849 outlined in [55]) and Delta method (also known as Sobel test [91]) for the Product method estimate. 850 Further details on performing mediation analysis are available in the Supplementary materials of our 851 previous work [10]). The mediation analysis calculations are presented in **Supplementary Note 2**. 852

853 Code availability

854

855 All analyses in this study are available at: <u>https://github.com/mvab/mammographic_density_mr</u> 856

857 Data availability

858

859 The GWAS data for BCAC 2017 breast cancer (ieu-a-1126, ieu-a-1127, ieu-a-1128) and age at 860 menarche (ukb-b-3768) was accessed from OpenGWAS (https://gwas.mrcieu.ac.uk). The BCAC 2020 861 subtype data molecular is available at https://bcac.ccge.medschl.cam.ac.uk/bcacdata/ 862 oncoarray/oncoarray-and-combined-summary-result/. Childhood and adult body size GWAS data was 863 published in ref [5].

perpetuity. It is made available under a CC-BY 4.0 International license .

This study uses data from a GWAS of mammographic density (ref [32]). The RPGEH genotype data are available upon application to the KP Research Bank

(https://researchbank.kaiserpermanente.org/). Additional relevant information is available from the authors upon reasonable request.

Funding acknowledgements

M.V. is supported by the University of Bristol Alumni Fund (Professor Sir Eric Thomas Scholarship).

B.L.L. is supported by the University of Bristol Vice-Chancellor's fellowship, Academy of Medical Sciences, Elizabeth Blackwell Institute for Health Research (University of Bristol) and the Wellcome Trust Institutional Strategic Support Fund (ISSF3 (204813/Z/16/Z) and AMS (SBF003/1170)).

M.V., G.D.S., E.S., T.G.R., R.C.R. work in the UK Medical Research Council Integrative Epidemiology Unit at the University of Bristol supported by Medical Research Council (MC UU 00032/01, MC_UU_00032/03, MC_UU_00032/04). This work is also supported by a Cancer Research UK programme grant (the Integrative Cancer Epidemiology Programme) (C18281/A29019).

W.S., L.A.H., J.H.R., S.E.A are supported by the U.S. National Institutes of Health (R01CA237541, R01CA264987, R01CA166827).

- Authors' contributions

M.V., B.L.L., R.C.R., G.D.S., T.G.R., E.S. conceived and designed the study. M.V. performed the analyses, interpreted the results, and wrote the initial draft of the manuscript as well as subsequent drafts with critical input on results interpretation and manuscript revisions from E.S., B.L.L., T.G.R., G.D.S., R.C.R., W.S., L.A.H., J.H.R., S.E.A. Access to mammographic density data was provided by W.S., L.A.H., J.H.R., S.E.A.; J.H.R. performed genome-wide association studies of mammographic density phenotypes unadjusted for BMI.

The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. All authors read and approved the final manuscript.

We would also like to acknowledge Tom Gaunt and Tim Robinson for thoughtful project discussions.

Competing interests

T.G.R. is employed by GSK outside of this work, for unrelated research. All other authors declare no competing interests.

perpetuity. It is made available under a CC-BY 4.0 International license .

918 **References**

- H. Sung *et al.*, "Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," *CA. Cancer J. Clin.*, vol. 0, no. 0, pp. 1– 41, 2021.
- [2] K. L. Britt, J. Cuzick, and K. A. Phillips, "Key steps for effective breast cancer prevention,"
 Nature Reviews Cancer, vol. 20, no. 8. Nature Publishing Group, pp. 417–436, 11-Jun-2020.
- H. J. Baer, S. S. Tworoger, S. E. Hankinson, and W. C. Willett, "Body fatness at young ages and risk of breast cancer throughout life," *Am. J. Epidemiol.*, vol. 171, no. 11, pp. 1183–1194, 2010.
- 928[4]A. Furer *et al.*, "Adolescent obesity and midlife cancer risk: a population-based cohort study of9292·3 million adolescents in Israel," *Lancet Diabetes Endocrinol.*, vol. 8, no. 3, pp. 216–225,9302020.
- T. G. Richardson, E. Sanderson, B. Elsworth, K. Tilling, and G. Davey Smith, "Use of genetic variation to separate the effects of early and later life adiposity on disease risk: Mendelian randomisation study," *BMJ*, vol. 369, 2020.
- 934 [6] B. W. Jensen *et al.*, "Childhood body mass index trajectories, adult-onset type 2 diabetes, and obesity-related cancers," *J. Natl. Cancer Inst.*, vol. 115, no. 1, pp. 43–51, Jan. 2023.
- 936 [7] Y. Hao *et al.*, "Reassessing the causal role of obesity in breast cancer susceptibility a
 937 comprehensive multivariable Mendelian randomization investigating the distribution and timing
 938 of exposure," *Int. J. Epidemiol.*, vol. 52, no. 1, p. 58, Jul. 2022.
- S. Ebrahim and G. Davey Smith, "Mendelian randomization: Can genetic epidemiology help
 redress the failures of observational epidemiology?," *Int. J. Epidemiol.*, vol. 32, no. 1, pp. 1–22,
 Feb. 2003.
- 942 [9] E. Sanderson *et al.*, "Mendelian randomization," *Nat. Rev. Methods Prim.*, vol. 2, no. 1, Dec.
 943 2022.
- M. Vabistsevits, G. Davey Smith, E. Sanderson, T. G. Richardson, B. Lloyd-Lewis, and R. C.
 Richmond, "Deciphering how early life adiposity influences breast cancer risk using Mendelian randomization," *Commun. Biol.*, vol. 5, no. 1, 2022.
- 947 [11] N. F. Boyd *et al.*, "Heritable dense breasts & breast cancer," vol. 6, no. October, pp. 798–808, 2005.
- 949 [12] A. Pettersson *et al.*, "Mammographic density phenotypes and risk of breast cancer: a meta-950 analysis," *J. Natl. Cancer Inst.*, vol. 106, no. 5, May 2014.
- [13] K. A. Bertrand *et al.*, "Dense and nondense Mammographic area and risk of breast cancer by age and tumor characteristics," *Cancer Epidemiol. Biomarkers Prev.*, vol. 24, no. 5, pp. 798–953
 809, May 2015.
- V. A. McCormack and I. Dos Santos Silva, "Breast density and parenchymal patterns as markers of breast cancer risk: A meta-analysis," *Cancer Epidemiol. Biomarkers Prev.*, vol. 15, no. 6, pp. 1159–1169, Jun. 2006.
- 957 [15] J. Stone *et al.*, "The heritability of mammographically dense and nondense breast tissue," 958 *Cancer Epidemiol. Biomarkers Prev.*, vol. 15, no. 4, pp. 612–617, Apr. 2006.
- 959 [16] G. Kleinstern *et al.*, "Association of mammographic density measures and breast cancer 960 'intrinsic' molecular subtypes," vol. 187, pp. 215–224, 2021.
- 961 [17] M. S. Shawky, C. W. Huo, M. A. Henderson, A. Redfern, K. Britt, and E. W. Thompson, "A
 962 review of the influence of mammographic density on breast cancer clinical and pathological
 963 phenotype," *Breast Cancer Res. Treat.* 2019 1772, vol. 177, no. 2, pp. 251–276, Jun. 2019.
- 964 [18] A. G. Ghadge, P. Dasari, J. Stone, E. W. Thompson, R. L. Robker, and W. V. Ingman,
 965 "Pubertal mammary gland development is a key determinant of adult mammographic density,"
 966 Semin. Cell Dev. Biol., vol. 114, no. July, pp. 143–158, 2021.
- 967 [19] S. X. Sun *et al.*, "Breast physiology: Normal and abnormal development and function," in *The* 968 *Breast: Comprehensive Management of Benign and Malignant Diseases*, Elsevier, 2017, pp.
 969 37-56.e6.
- 970 [20] S. E. Alexeeff *et al.*, "Age at menarche and late adolescent adiposity associated with mammographic density on processed digital mammograms in 24,840 women," *Cancer Epidemiol. Biomarkers Prev.*, vol. 26, no. 9, pp. 1450–1458, Sep. 2017.
- 973 [21] S. V. Ward *et al.*, "The association of age at menarche and adult height with mammographic density in the International Consortium of Mammographic Density," *Breast Cancer Res.*, vol. 24, no. 1, pp. 1–16, Dec. 2022.
- 976[22]Collaborative Group on Hormonal Factors in Breast Cancer, "Menarche, menopause, and977breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast

978 979		cancer from 117 epidemiological studies," <i>Lancet Oncol.</i> , vol. 13, no. 11, pp. 1141–1151, 2012
980	[23]	G. V. Dall and K. L. Britt, "Estrogen Effects on the Mammary Gland in Early and Late Life and
981 982 983	[24]	N. Brown <i>et al.</i> , "The relationship between breast size and anthropometric characteristics,"
984	[25]	M. B. Terry <i>et al.</i> , "Do Birth Weight and Weight Gain during Infancy and Early Childhood
985 986		Explain Variation in Mammographic Density in Women in Midlife? Results from Cohort and Sibling Analyses " Am. J. Epidemiol. vol. 188, pp. 2, pp. 294–304, 2019
987	[26]	F. Juul, V. W. Chang, P. Brar, and N. Parekh, "Birth weight, early life weight gain and age at
988 989		menarche: a systematic review of longitudinal studies," <i>Obes. Rev.</i> , vol. 18, no. 11, pp. 1272–1288, 2017.
990 991	[27]	C. Prince, L. D. Howe, G. C. Sharp, A. Fraser, and R. C. Richmond, "Establishing the
992		randomization analysis," <i>medRxiv</i> , p. 2023.03.03.23286615, Mar. 2023.
993	[28]	Z. J. Andersen, J. L. Baker, K. Bihrmann, I. Vejborg, T. I. A. Sørensen, and E. Lynge, "Birth
994 995		weight, childhood body mass index, and height in relation to mammographic density and breast cancer: A register-based cohort study " Breast Cancer Res. vol. 16, po. 1, pp. 1–11
996		Jan. 2014.
997	[29]	J. L. Hopper et al., "Childhood body mass index and adult mammographic density measures
998	1201	that predict breast cancer risk," <i>Breast Cancer Res. Treat.</i> , vol. 156, no. 1, pp. 163–170, 2016.
999 1000	[30]	Postmenopausal Women " Cancer Prev. Res. vol. 13 no. 5 pp. 475–482, 2020
1001	[31]	M. S. Rice <i>et al.</i> , "Mammographic density and breast cancer risk: A mediation analysis,"
1002		Breast Cancer Res., vol. 18, no. 1, p. 94, Sep. 2016.
1003	[32]	W. Sieh <i>et al.</i> , "Identification of 31 loci for mammographic density phenotypes and their associations with breast capeer risk." <i>Nat. Commun.</i> , vol. 11, pp. 1, Dec. 2020.
1004	[33]	F. Chen <i>et al.</i> , "Mendelian randomization analyses of 23 known and suspected risk factors and
1006	[]	biomarkers for breast cancer overall and by molecular subtypes," Int. J. Cancer, Apr. 2022.
1007	[34]	E. Sanderson, "Multivariable Mendelian Randomization and Mediation," <i>Cold Spring Harb.</i>
1008	[25]	Perspect. Med., 2020.
1009	[35]	H. Zhang <i>et al.</i> , "Genome-wide association study identifies 32 novel breast cancer
1011	[]	susceptibility loci from overall and subtype-specific analyses," Nat. Genet., vol. 52, no. 6, pp.
1012	1071	572–581, Jun. 2020.
1013	[37]	M. Verbanck, C. Y. Chen, B. Neale, and R. Do, "Detection of widespread horizontal pleiotropy
1014		diseases." Nat. Genet. 2018 505. vol. 50. no. 5. pp. 693–698. Apr. 2018.
1016	[38]	C. N. Foley, A. M. Mason, P. D. W. Kirk, and S. Burgess, "MR-Clust: Clustering of genetic
1017		variants in Mendelian randomization with similar causal estimates," <i>Bioinformatics</i> , vol. 37, no.
1018	[39]	4, pp. 531–541, 2021. I Bowden <i>et al.</i> "Improving the visualization, interpretation and analysis of two-sample
1020	[00]	summary data Mendelian randomization via the Radial plot and Radial regression," Int. J.
1021		<i>Epidemiol.</i> , vol. 47, no. 4, pp. 1264–1278, Aug. 2018.
1022	[40]	L. A. C. Millard, N. M. Davies, N. J. Timpson, K. Tilling, P. A. Flach, and G. Davey Smith, "MR-
1023		PnevvAS: Hypothesis prioritization among potential causal effects of body mass index on many outcomes using Mendelian randomization." Sci. Rep. vol. 5, no. 1, no. 1–17, Nov
1025		2015.
1026	[41]	V. W. Skrivankova et al., "Strengthening the reporting of observational studies in epidemiology
1027		using mendelian randomisation (STROBE-MR): explanation and elaboration," <i>BMJ</i> , vol. 375,
1026	[42]	V W Skrivankova et al. "Strengthening the Reporting of Observational Studies in
1030	['-]	Epidemiology Using Mendelian Randomization: The STROBE-MR Statement," JAMA, vol.
1031		326, no. 16, pp. 1614–1621, Oct. 2021.
1032	[43]	J. Bowden, G. Davey Smith, and S. Burgess, "Mendelian randomization with invalid
1033		instruments. Effect estimation and bias detection through Egger regression, <i>Int. J. Epidemiol.</i> , vol. 44, no. 2, pp. 512–525. May 2015.
1035	[44]	J. Bowden, G. Davey Smith, P. C. Haycock, and S. Burgess, "Consistent Estimation in
1036		Mendelian Randomization with Some Invalid Instruments Using a Weighted Median

1037 Estimator," Genet. Epidemiol., vol. 40, no. 4, pp. 304–314, May 2016.

1038 1039	[45]	J. Bowden <i>et al.</i> , "Improving the accuracy of two-sample summary-data Mendelian randomization: Moving beyond the NOME assumption," <i>Int. J. Epidemiol.</i> , vol. 48, no. 3, pp. 749–744
1040	[40]	728–742, 2019. E. Osadawa M. Osillas and I. Dandar, "Testing and second in factorial static
1041	[46]	E. Sanderson, W. Spiller, and J. Bowden, "Lesting and correcting for weak and pleiotropic
1042		Instruments in two-sample multivariable Mendelian randomization," Stat. Med., vol. 40, no. 25,
1043	F 4 - 71	pp. 5434–5452, Apr. 2021.
1044	[47]	J. Yarmolinsky et al., "Causal inference in cancer epidemiology: What is the role of mendelian
1045		randomization?," Cancer Epidemiology Biomarkers and Prevention, vol. 27, no. 9. American
1046		Association for Cancer Research Inc., pp. 995–1010, 01-Sep-2018.
1047	[48]	S. Lindström et al., "Genome-wide association study identifies multiple loci associated with
1048		both mammographic density and breast cancer risk," Nat. Commun., vol. 5, p. 5303, Oct.
1049		2014.
1050	[49]	P. Fernandez-Navarro et al., "Genome wide association study identifies a novel putative
1051		mammographic density locus at 1q12-q21," Int. J. Cancer, vol. 136, no. 10, pp. 2427–2436,
1052		May 2015.
1053	[50]	N. Eriksson et al., "Genetic variants associated with breast size also influence breast cancer
1054		risk," <i>BMC Med. Genet.</i> , vol. 13, Jun. 2012.
1055	[51]	M. J. Sherratt, J. C. McConnell, and C. H. Streuli, "Raised mammographic density: Causative
1056		mechanisms and biological consequences," Breast Cancer Res., vol. 18, no. 1, pp. 1–9, May
1057		2016.
1058	[52]	N. F. Boyd, L. J. Martin, M. J. Yaffe, and S. Minkin, "Mammographic density and breast cancer
1059		risk: current understanding and future prospects." Breast Cancer Res., vol. 13, no. 6, Nov.
1060		2011.
1061	[53]	F. P. Hartwig, K. Tilling, G. Davey Smith, D. A. Lawlor, and M. C. Borges, "Bias in two-sample
1062	[]	Mendelian randomization when using heritable covariable-adjusted summary associations."
1063		Int. J. Epidemiol., vol. 50, no. 5, pp. 1639–1650, 2021.
1064	[54]	J. Gilbody, M. C. Borges, G. Davey Smith, and E. Sanderson, "Multivariable MR can mitigate
1065	[0.]	bias in two-sample MR using covariable-adjusted summary associations " medRxiv n
1066		2022 07 19 22277803 . Jul 2022
1067	[55]	S Burgess D. J. Thompson, J. M. B. Rees, F. R. Day, J. R. Perry, and K. K. Ong, "Dissecting
1068	[00]	causal pathways using mendelian randomization with summarized genetic data. Application to
1069		age at menarche and risk of breast cancer." Genetics vol. 207 no. 2 nn. 481–487. Oct. 2017
1070	[56]	A Balmain "Peto's paradox revisited: black box vs mechanistic approaches to understanding
1070	[00]	the roles of mutations and promoting factors in cancer." Fur J Enidemial vol 1 pp 1–8
1071		
1072	[57]	M Archer, P. Dasari, A. Evdokiou, and W. V. Ingman, "Biological mechanisms and therapeutic
1074	[07]	opportunities in mammographic density and breast cancer risk " <i>Cancers (Basel)</i> vol 13 no
1075		21 nn 1 21 2021
1075	[59]	21, μp. 1-21, 2021. W. Mang at al. "Clustered Mondelian randomization analyses identify distinct and ennesing
1070	[30]	nathways in the association between genetically influenced insulin-like growth factor 1 and
1077		type 2 diabetes mellitus " Int. I Enidemial yol 51 pp. 6 pp. 1874 1885 Jun 2022
1070	[50]	type 2 diabetes mellitus, <i>mit. J. Epidemiol.</i> , vol. 51, no. 0, pp. 1074–1000, Jun. 2022.
1079	[39]	J. S. Didnu, K. Humphreys, J. Li, K. Kansson, F. Hall, and K. Ozene, "Common genetic
1000		Pop vol 20 pp 1 Apr 2019
1001	1601	Res., Vol. 20, 110. 1, Apl. 2010. A. Kharahid Shamahiri M. Alidayat M. Hammati Nakandai A. Deadar, and E. Afzaliayan
1002	[00]	A. Khorshiu Shamshin, W. Aluousi, W. Hemmali Nokandel, A. Pasuar, and F. Alzaijavan,
1003		Genetic architecture of manimographic density as a risk factor for breast cancer: a systematic
1084	1041	review," <i>Clin. Transi. Oncol. 2023</i> , pp. 1–19, Jan. 2023.
1085	[61]	H. Chen et al., "Genome-wide and transcriptome-wide association studies of mammographic
1000	1001	density pnenotypes reveal hovel loci, <i>Daniel S. McConnell</i> , vol. 21, no. 1, p. 27, Dec. 2022.
1087	[62]	Y. Liu et al., "A genome-wide association study of mammographic texture variation," Breast
1000	1001	Cancer Res. 2022 241, vol. 24, no. 1, pp. 1–15, Nov. 2022.
1089	[63]	E. I. vvarner et al., "Automated percent mammographic density, mammographic texture
1090		variation, and risk of breast cancer: a nested case-control study," NPJ breast cancer, vol. 7,
1091	10.43	no. 1, Dec. 2021.
1092	[64]	A. Burknolder et al., "Investigation of the adolescent female breast transcriptome and the
1093	10	impact of obesity," Breast Cancer Res., vol. 22, no. 1, pp. 1–14, 2020.
1094	[65]	Y. Banda et al., "Characterizing race/ethnicity and genetic ancestry for 100,000 subjects in the
1095		genetic epidemiology research on adult health and aging (GERA) cohort," Genetics, vol. 200,
1096	10.05	no. 4, pp. 1285–1295, Aug. 2015.
1097	[66]	M. N. Kvale et al., "Genotyping informatics and quality control for 100,000 subjects in the

1098		genetic epidemiology research on adult health and aging (GERA) cohort," <i>Genetics</i> , vol. 200,
11099	[67]	C. Sudlow <i>et al.</i> , "UK Biobank: An Open Access Resource for Identifying the Causes of a Wide
1101		Range of Complex Diseases of Middle and Old Age," PLoS Med., vol. 12, no. 3, Mar. 2015.
1102	[68]	M. Brandkvist <i>et al.</i> , "Separating the genetics of childhood and adult obesity: a validation study
1103		of genetic scores for body mass index in adolescence and adulthood in the HUNT Study,"
1104	[69]	T G Richardson et al. "Evaluating the direct effects of childhood adiposity on adult systemic
1106	[00]	metabolism: a multivariable Mendelian randomization analysis," Int. J. Epidemiol., Mar. 2021.
1107	[70]	B. Elsworth et al., The MRC IEU OpenGWAS data infrastructure. 2020, p. 2020.08.10.244293.
1108	[71]	H. Zhang et al., "Genome-wide association study identifies 32 novel breast cancer
1109	1701	susceptibility loci from overall and subtype-specific analyses," <i>Nat. Genet.</i>
1110	[72]	D. A. Lawlor, R. M. Harbord, J. A. C. Sterne, N. Timpson, and G. Davey Smith, "Mendelian
1112		Stat Med vol 27 no 8 pp 1133–1163 Apr 2008
1113	[73]	S. Burgess, R. A. Scott, N. J. Timpson, G. Davey Smith, and S. G. Thompson, "Using
1114		published data in Mendelian randomization: A blueprint for efficient identification of causal risk
1115		factors," Eur. J. Epidemiol., vol. 30, no. 7, pp. 543–552, Jul. 2015.
1116	[74]	S. Burgess, A. Butterworth, and S. G. Thompson, "Mendelian randomization analysis with
1110		multiple genetic variants using summarized data, <i>Genet. Epidemiol.</i> , vol. 37, no. 7, pp. 658–
1119	[75]	C. L. Relton and G. Davey Smith. "Two-step epigenetic mendelian randomization: A strategy
1120	[. 0]	for establishing the causal role of epigenetic processes in pathways to disease," Int. J.
1121		<i>Epidemiol.</i> , vol. 41, no. 1, pp. 161–176, 2012.
1122	[76]	J. Zheng <i>et al.</i> , "Recent Developments in Mendelian Randomization Studies," <i>Curr. Epidemiol.</i>
1123	[77]	Reports, vol. 4, no. 4, pp. 330–345, 2017.
1124	[//]	E. Sanderson, G. Davey Smith, F. Windmeijer, and J. Bowden, An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data
1126		settings," Int. J. Epidemiol., vol. 48, no. 3, pp. 713–727, Jun. 2019.
1127	[78]	S. Burgess and S. G. Thompson, "Multivariable Mendelian randomization: The use of
1128		pleiotropic genetic variants to estimate causal effects," Am. J. Epidemiol., vol. 181, no. 4, pp.
1129	1701	251–260, 2015.
1130	[/9]	J. M. B. Rees, A. M. Wood, and S. Burgess, Extending the MR-Egger method for multivariable Mendelian randomization to correct for both measured and unmeasured
1132		pleiotropy," Stat. Med., vol. 36, no. 29, pp. 4705–4718, Dec. 2017.
1133	[80]	G. Hemani <i>et al.</i> , "The MR-base platform supports systematic causal inference across the
1134		human phenome," <i>Elife</i> , vol. 7, May 2018.
1135	[81]	S. Burgess and S. G. Thompson, "Avoiding bias from weak instruments in Mendelian
1136	1001	randomization studies," Int. J. Epidemiol., vol. 40, no. 3, pp. 755–764, Jun. 2011.
1138	[oz]	imprecisely measured traits using GWAS summary data " PLoS Genet vol 13 no 11 no 1-
1139		22, 2017.
1140	[83]	S. Burgess, C. N. Foley, and V. Zuber, "Inferring causal relationships between risk factors and
1141		outcomes using genetic variation," Handb. Stat. Genomics, vol. 1, pp. 651–677, 2019.
1142	[84]	M. A. Kamat <i>et al.</i> , "PhenoScanner V2: an expanded tool for searching human genotype-
1143	[95]	phenotype associations," <i>Bioinformatics</i> , vol. 35, no. 22, pp. 4851–4853, Nov. 2019.
1145	[00]	Bioinformatics vol 32 no 20 no 3207–3209 Oct 2016
1146	[86]	K. Watanabe, E. Taskesen, A. Van Bochoven, and D. Posthuma, "Functional mapping and
1147		annotation of genetic associations with FUMA," Nat. Commun., vol. 8, no. 1, Dec. 2017.
1148	[87]	M. V. Kuleshov <i>et al.</i> , "Enrichr: a comprehensive gene set enrichment analysis web server
1149	1001	2016 update," Nucleic Acids Res., vol. 44, no. W1, pp. W90–W97, 2016.
1150	႞၀၀]	cL. Poon, ReactomeContentService4R. Intenace for the Reactome Content Service [R nackage] " 2022
1152	[89]	A. R. Carter <i>et al.</i> . "Mendelian randomisation for mediation analysis: Current methods and
1153	r - 1	challenges for implementation," European Journal of Epidemiology. 2021.
1154	[90]	S. Burgess, R. M. Daniel, A. S. Butterworth, and S. G. Thompson, "Network Mendelian
1155		randomization: Using genetic variants as instrumental variables to investigate mediation in
0011		causai paunways, Int. J. Epidemioi., vol. 44, no. 2, pp. 484–495, 2015.

1157 [91] M. E. Sobel, "Asymptotic Confidence Intervals for Indirect Effects in Structural Equation

		Models,"	Sociol.	Methodol.,	vol. 1	13, pp.	290-312,	1982.
--	--	----------	---------	------------	--------	---------	----------	-------

1160

1163